Repligen Corporation
RGEN
$2.83 (1.92%)
1D
1W
3M
1Y
5Y
ALL
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 5 days ago • RGEN
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
Zacks Investment Research • 6 days ago • RGEN
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
MarketBeat • 7 days ago • RGEN
Repligen Q2 Earnings Call Highlights
Zacks Investment Research • 7 days ago • RGEN
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
GlobeNewsWire • 7 days ago • RGEN
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.